Nventa granted U.S. patent covering heat shock protein fusion to treat anogenital warts

07-May-2007

Nventa Biopharmaceuticals Corporation announced that the U.S. Patent and Trademark Office has issued Patent Number 7,211,411 B2 to Nventa covering the use of HspE7, the Company's investigational therapeutic vaccine for human papillomavirus (HPV)-related diseases, to treat patients with anogenital warts. This new U.S. patent covers a method of treating a patient with anogenital warts using a fusion protein comprised of a heat shock protein from the Hsp60 family, which includes Hsp65, and an HPV (type 16) E7 antigen. This patent provides additional patent exclusivity for HspE7 to treat anogenital warts patients through September 2022.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances